Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.

BACKGROUND Regimens containing three nucleoside reverse-transcriptase inhibitors offer an alternative to regimens containing nonnucleoside reverse-transcriptase inhibitors or protease inhibitors for the initial treatment of human immunodeficiency virus type 1 (HIV-1) infection, but data from direct comparisons are limited. METHODS This randomized, double-blind study involved three antiretroviral regimens for the initial treatment of subjects infected with HIV-1: zidovudine-lamivudine-abacavir, zidovudine-lamivudine plus efavirenz, and zidovudine-lamivudine-abacavir plus efavirenz. RESULTS We enrolled a total of 1147 subjects with a mean baseline HIV-1 RNA level of 4.85 log10 (71,434) copies per milliliter and a mean CD4 cell count of 238 per cubic millimeter were enrolled. A scheduled review by the data and safety monitoring board with the use of prespecified stopping boundaries led to a recommendation to stop the triple-nucleoside group and to present the results in the triple-nucleoside group in comparison with pooled data from the efavirenz groups. After a median follow-up of 32 weeks, 82 of 382 subjects in the triple-nucleoside group (21 percent) and 85 of 765 of those in the combined efavirenz groups (11 percent) had virologic failure; the time to virologic failure was significantly shorter in the triple-nucleoside group (P<0.001). This difference was observed regardless of the pretreatment HIV-1 RNA stratum (at least 100,000 copies per milliliter or below this level; P< or =0.001 for both comparisons). Changes in the CD4 cell count and the incidence of grade 3 or grade 4 adverse events did not differ significantly between the groups. CONCLUSIONS In this trial of the initial treatment of HIV-1 infection, the triple-nucleoside combination of abacavir, zidovudine, and lamivudine was virologically inferior to a regimen containing efavirenz and two or three nucleosides.

[1]  Elizabeth Connick,et al.  Antiretroviral-drug resistance among patients recently infected with HIV. , 2002, The New England journal of medicine.

[2]  R. Wallace,,et al.  Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study. , 2001, The Journal of infectious diseases.

[3]  M A Fischl,et al.  A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. , 1997, The New England journal of medicine.

[4]  M. Fischl,et al.  Mutations in HIV-1 Reverse Transcriptase during Therapy with Abacavir, Lamivudine and Zidovudine in HIV-1-Infected Adults with No Prior Antiretroviral Therapy , 2002, Antiviral therapy.

[5]  C. Petropoulos,et al.  Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information. , 2002, Journal of acquired immune deficiency syndromes.

[6]  E A Emini,et al.  Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. , 1997, The New England journal of medicine.

[7]  J. Kahn,et al.  Time trends in primary HIV-1 drug resistance among recently infected persons. , 2002, JAMA.

[8]  Calvin Cohen,et al.  Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease , 1998, The Lancet.

[9]  Lee-Jen Wei,et al.  Combining dependent tests with incomplete repeated measurements , 1985 .

[10]  M. Schambelan,et al.  Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. , 2000 .

[11]  Joseph Quinn,et al.  Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults , 2001, AIDS.

[12]  M. Moroni,et al.  A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients , 2003, AIDS.

[13]  L. Bacheler,et al.  Human Immunodeficiency Virus Type 1 Mutations Selected in Patients Failing Efavirenz Combination Therapy , 2000, Antimicrobial Agents and Chemotherapy.

[14]  David A. Cooper,et al.  A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors , 1998, AIDS.

[15]  P. Massip,et al.  Impact of protease inhibitors on AIDS‐defining events and hospitalizations in 10 French AIDS reference centres , 1997, AIDS.

[16]  P. O'Brien,et al.  A multiple testing procedure for clinical trials. , 1979, Biometrics.

[17]  K. Tashima,et al.  Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. , 1999, The New England journal of medicine.

[18]  F. Hecht,et al.  Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population , 2000, AIDS.

[19]  F. Goebel,et al.  Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV‐1‐infected patients , 1998, AIDS.

[20]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[21]  S. Hammer,et al.  Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. , 2001, JAMA.

[22]  P. Armitage,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. , 1976, British Journal of Cancer.

[23]  A. Antinori,et al.  Treatment‐Related Factors and Highly Active Antiretroviral Therapy Adherence , 2002, Journal of acquired immune deficiency syndromes.

[24]  F. Brun-Vézinet,et al.  Triple Nucleoside Combination Zidovudine/Lamivudine/Abacavir versus Zidovudine/Lamivudine/Nelfinavir as First-Line Therapy in HIV-1-Infected Adults: A Randomized Trial , 2002, Antiviral therapy.

[25]  John W. Mellors,et al.  Panel on Clinical Practices for Treatment of HIV Infection , 2000 .

[26]  P. Narciso,et al.  Adherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than in those receiving protease inhibitor-containing regimens. , 2003, AIDS.

[27]  B. Turnbull,et al.  Group Sequential Methods with Applications to Clinical Trials , 1999 .

[28]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.

[29]  Michael S Saag,et al.  Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. , 2002, JAMA.

[30]  S. Pocock.  Group sequential methods in the design and analysis of clinical trials , 1977 .

[31]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[32]  Susan Swindells,et al.  Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection , 2000, Annals of Internal Medicine.

[33]  K. K. Lan,et al.  Discrete sequential boundaries for clinical trials , 1983 .

[34]  D. Podzamczer,et al.  A Randomized Clinical Trial Comparing Nelfinavir Or Nevirapine Associated to Zidovudine/Lamivudine in HIV-Infected Naive Patients (The Combine Study) , 2001, Antiviral therapy.

[35]  K. Tashima,et al.  Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  J. J. Henning,et al.  Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.